KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

D. Rodriguez Abreu, M. C. Garassino, E. Esteban, G. Speranza, E. Felip, M. Domine, M. J. Hochmair, S. F. Powell, S. Y.S. Cheng, H. Bischoff, N. Peled, R. Hui, M. Reck, E. B. Garon, M. Boyer, F. Grossi, R. Jennens, J. Yang, M. C. Pietanza, S. M. Gadgeel

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)viii529-viii530
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this